Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger

 

• TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway
• $31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025
• TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents potential upside partnering opportunities
• Companies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ET

The companies plan to hold a joint conference call and webcast today, April 3, 2024 at 8:30 AM ET to discuss the Merger details.

Interested participants and investors may access the conference call and webcast via the Investors section of the Kintara website at www.kintara.com and on TuHURA's website,  tuhurabio.com. A webcast replay will be available following the live event and will be accessible for 90 days.

https://www.prnewswire.com/news-releases/kintara-therapeutics-and-tuhura-biosciences-enter-into-definitive-merger-agreement-302106737.html